Cardiac functional status of patients with Chronic Kidney Disease: A cross sectional study

Mohammad Ibrahim¹, Khan Md. Nazmus Saqeb²*, Rezwana Sobhan³, Nadira Haque⁴
DOI: https://doi.org/10.3329/bccj.v10i2.62201

Abstract:

**Background:** In the recent years, the prevalence of chronic kidney disease (CKD) has increased in the community. CKD has been associated with several cardiac diseases. The aim of the study was to assess the cardiac status of the CKD patients.

**Methods:** This cross-sectional study was done in Rangpur Medical College Hospital, Rangpur from June 2013 to November 2013. A total of 50 CKD patients were selected by convenient type of sampling. An informed written consent was taken before enrolling the patients into the study. All the data were recorded in a pre-structured questionnaire. Analysis of the data was done by SPSS V.22. A P value of <0.05 was considered as significant.

**Results:** A total of 50 cases were studied; age ranging from 23 years to 75 years and the mean age ± SD was 45.8 ± 11.56. We study showed that 30% of patients had cardiac dysfunction, among them 18% had systolic dysfunction and 12% had diastolic dysfunction. In the study, among the diastolic dysfunction 10% had slow relaxation pattern and 02% had restrictive pattern of diastolic dysfunction. In our study, we have seen that 36% patients had left ventricular hypertrophy. ECG findings showed that 36% of patients had LVH, 6% showed anterolateral ischaemia, 6% showed inferior ischaemia, 4% showed sinus bradycardia, 2% sinus tachycardia, 2% anterior ischaemia and 2% septal ischaemia. In our study chest X-ray P/A view showed 30% had cardiomegaly, 4% had pulmonary oedema, 4% had pleural effusion and 62% had normal findings. When we staged the CKD with the GFR, it was shown that 90% patients had GFR < 15, 6% had GFR in between 30—59 and 4% had in between 15-29ml/min. Systolic dysfunction was more (8%) in patients having GFR < 15, whereas it was only 1% in patients having GFR in between 30—59.

**Conclusion:** This study an suggested association between chronic kidney disease (CKD) and cardiac dysfunction, both systolic and diastolic. It demonstrated a high prevalence left ventricular hypertrophy (LVH) as well. Early detection and treatment of causes of CKD should be pursued aggressively at the earliest possible time to prevent cardiovascular complications and thus reduce morbidity.

**Keywords:** Cardiac function, Chronic Kidney Disease (CKD).
Structural and Functional changes of the heart in renal failure. The risk of cardiovascular disease (CVD) in patients with Chronic renal failure appears to be far greater than in the general population. Patients with CRF should be considered in the highest risk group for subsequent cardiovascular disease CVD events. Treatment recommendations based on CVD risk stratification should take into account this “highest risk” status of the patient with CRF. Among patients treated by hemodialysis or peritoneal dialysis, the prevalence of coronary artery disease is approximately 40% and the prevalence of Left Ventricular Hypertrophy is approximately 75%. Patients with end-stage renal disease (ESRD) are at a much higher risk of Cardiovascular disease than the general population.

The objective of this study was to assess cardiac functional status of the CKD patients. In the recent years, the prevalence of chronic kidney disease (CKD) has increased in the community. Even in advanced countries, CKD remains a major health problem causing cardiovascular diseases such as congestive cardiac failure, myocardial infarction, hypertension, stroke, and sudden cardiac death. In 1997, annual report of US renal data system (USRDS) revealed that morbidity in patients with CRF is attributed mainly to cardiac causes, which accounts for 49% of the cases. Cardiac disease is the major cause of death in dialysis population accounting for 40% of death in international registries and left ventricular hypertrophy is an independent predictor of survival present in approximately 70% of patients at the initiation of dialysis. Cardiac functional status abnormalities including left ventricular hypertrophy (LVH) is a major finding in chronic kidney disease (CKD) and there is scanty information on the prevalence of cardiac functional abnormalities in these patients. Aim of the present study was to estimate the prevalence of cardiac functional abnormalities in patients with Chronic Kidney Disease and to find out correlation of cardiac functional status with the severity of Chronic Kidney Disease.

Methods
This cross-sectional study was done in Rangpur Medical College Hospital, Rangpur from June 2013 to November 2013. Convenient type of sampling technique was applied. All the CKD patients who were of more than 18 years of age and were willing to give voluntary consent were included in the study. Patients unwilling to take part in the study were excluded. Detailed history was taken and thorough examination was done in each case. Relevant investigations were done in every individual including an ECG (12 leads), Chest X-ray and an Echocardiography.

Statistics
All the data were collected in a predesigned questionnaire. Statistical analyses were carried out by using the Statistical Package for Social Sciences version 22.0 for Windows (SPSS Inc., Chicago, Illinois, USA). Continuous variables were expressed as means, and categorical variables as frequencies and percentages. A p-value <0.05 was considered as significant.
results

In our study, mean age with standard deviation was 45.80 ±11.46 years. Out of 50 CKD patients, 32 were male (64%) and rest were female (36%).

Table 1: eGFR of the study populations (N=50)

| eGFR   | Frequency | Percentage |
|--------|-----------|------------|
| 30---59| 03        | 06         |
| 15---29| 02        | 04         |
| <15    | 45        | 90         |

Table 2: Cardiac dysfunction of the study populations(N=50)

| Cardiac dysfunction | Frequency | Percentage |
|---------------------|-----------|------------|
| Absent              | 35        | 70         |
| Present             | 15        | 30         |
| Systolic dysfunction|           |            |
| Absent              | 41        | 82         |
| Present             | 09        | 18         |
| Diastolic dysfunction|          |            |
| Absent              | 44        | 88         |
| Present             | 06        | 12         |

Table 3: Relation between stages of CKD with cardiac dysfunction

| Stage (with eGFR) | Cardiac dysfunction | Percentage | P value |
|-------------------|---------------------|------------|---------|
|                   | Absent              | Present    |         |
| Stage 5(<15)      | 31                  | 14         | 31.11   | <0.001 |
| Stage 4(15-29)    | 02                  | 00         | 00      |         |
| Stage 3(30-59)    | 02                  | 01         | 33.33   |         |

Table 4: Relation between stages of CKD with systolic dysfunction

| Stage (with eGFR) | Systolic dysfunction | Percentage | P value |
|-------------------|----------------------|------------|---------|
|                   | Absent               | Present    |         |
| Stage 5(<15)      | 37                   | 08         | 17.77   | <0.05  |
| Stage 4(15-29)    | 02                   | 00         | 00      |         |
| Stage 3(30-59)    | 02                   | 01         | 33.33   |         |

Table 5: Relation between stages of CKD with diastolic dysfunction

| Stage (with GFR) | Diastolic dysfunction | Percentage | P value |
|------------------|-----------------------|------------|---------|
|                   | Absent                | Present    |         |
| Stage 5(<15)     | 38                    | 07         | 15.55   | <0.005 |
| Stage 4(15-29)   | 02                    | 00         | 00      |         |
| Stage 3(30-59)   | 03                    | 00         | 00      |         |
Patients with a BMI of < 18.5 had greater cardiac dysfunction (35.71%) than those who had a BMI between 18.5—24.9 (28.57%). Lower BMI was associated with a higher prevalence of cardiac dysfunction. With increasing severity of anaemia, the prevalence of cardiac dysfunction increased. 44.44% patients with a Hb Level of less than 6 had cardiac dysfunction, whereas 30% patients with a Hb. Level between 6—9 mg/dl had cardiac dysfunction. In patients who had pedal edema, cardiac dysfunction was observed in 38.70% cases and 15.78% cardiac dysfunction was seen in patients without any pedal oedema.

In this study, 36% patients had Left Ventricular Hypertrophy (LVH) and 26% patients had pericardial effusion. ECG findings showed that 36% patients had LVH, 6% showed anterolateral ischaemia, 6% showed inferior ischaemia, 4% showed sinus bradycardia, 2% sinus tachycardia, 2% anterior ischaemia and 2% septal ischaemia. In our study chest X-ray P/A view showed 30% had cardiomegaly, 4% had pulmonary oedema, 4% had pleural effusion and 62% had normal findings.

Discussion

Premature cardiovascular disease is a significant cause of morbidity and mortality among patients with CKD. Four main structural abnormalities of the heart have been described in patients with CKD: LV hypertrophy, expansion of the nonvascular cardiac interstitium leading to inter-myocardioctyct fibrosis, changes in vascular architecture, and myocardial calcification. All these abnormalities promote systolic as well as diastolic LV dysfunction, which predisposes to symptomatic heart failure, which is a risk factor for premature death. Various diagnostic modalities, both invasive and noninvasive such as electrocardiography, echocardiography and radionuclide scans are utilized for diagnosing left ventricular hypertrophy and dysfunction. Echocardiography provides an excellent non-invasive method to delineate details of the anatomy of cardiac cavity, wall dimensions and wall movements. It is now increasingly used in the assessment of cardiac performance and is also invaluable in the demonstration of structural abnormalities such as LVH and pericardial effusion. Left ventricular hypertrophy is the single strongest independent predictor of adverse cardiovascular events and is a major echocardiographic finding in uremic patients. In our study, most CKD patients are of in the age group of 46 to 55 years (40%). In our study 66.66% patients of more than 55 years age had cardiac dysfunction. It is showed that with increasing age there is increase in the cardiac dysfunction. Kotchen et al. showed the prevalence of cardiac dysfunction among individuals aged >60, is 65.4 percent.13 Our study is consistent with these studies. In our study male patients had more (34.37%) cardiac dysfunction than female (22.2%). Ruixin et al. showed that sex differences in the prevalence of cardiac dysfunction may be mainly attributed to the differences in dietary habits, lifestyle choices, sodium and potassium intakes, physical activity level, and some genetic polymorphisms.

In our study 30% patients had cardiac dysfunction, whereas 70% had no cardiac dysfunction, in which 18% patients had systolic dysfunction and 12% patients had diastolic dysfunction. In the present study, out of 50 patients 18 (36%) patients had Left Ventricular Hypertrophy on Echocardiography which is comparatively similar to the study done by Parfrey P S et al 8 (41%), Rachel J Middleton, et al. 11 (41%) but lower to the study done by Tomilina N A et al. 14 (52.6%), Kale S A et al. 15 (54.7%), Goran J Paunovic et al. 9 (56.9%), Sanchari Datta et al. 10 (77%). In the present study, we found that LVH was more common in patients in the advanced stages of CKD. This is in concordance with the study done by Dangiri P et al. 2, Agarwal S et al. 3, Adeera Levin et al. 17 who also found a similar trend of LVH in patients of CKD.

In our study, stage 3 and stage 5 CKD patient had more or less same percentage of cardiac dysfunction (33.33% and 31.11% respectively) (Table 3). In respect of systolic dysfunction, stage 3 patients had more (33.33%) systolic dysfunction than stage 5 (17.77%). In respect of diastolic dysfunction, stage 5 patients had 15.55% diastolic dysfunction, where other stages had no diastolic dysfunction. In relation with BMI those with a BMI of < 18.5 had greater cardiac dysfunction (35.71%) and those who had a BMI of 18.5—24.9 had 28.57% cardiac dysfunction. Lower BMI was associated with a higher prevalence of cardiac dysfunction.16

With increasing the severity anaemia, the prevalence of cardiac dysfunction is increasing e.g. 44.44% cardiac dysfunction on in Hb. Level <6, 30% in Hb. Level 6—9 mg/dl, all of which is in concordance with study done by Agarwal S et al. 1 and Tomilina et al. 14. In patients those who had pedal edema, had cardiac dysfunction of 38.70% and those who did not, had 15.78% cardiac dysfunction. Oliveria et al. 19 observed that 40% patients associated with pedal edema had the cardiac dysfunction, which is very much consistent with this study. In this study, 26% patients had pericardial effusion. Roccella et al. shown that 30% of the patients had pericardial effusion20, this is more or less similar with our study.

Conclusion

Cardiac dysfunction was very common among patients with CKD. This study suggests that there is association between advancing stages of CKD and the presence of cardiac dysfunction. Further study with regression analysis is needed to confirm our findings. It demonstrated a high prevalence left ventricular hypertrophy (LVH) as well. Early detection and treatment of causes of CKD (Chronic Kidney Disease) should be pursued aggressively at the primary prevention level, as has been advocated by the international society of nephrology to reduce the effect of CKD and its attendant cardiac complication in the society. Various efforts aimed at prevention and control of left ventricular hypertrophy should be started early during the course of renal insufficiency.

References

1. Fassbinder W, Brunner FP, Brynger H. Combined report on regular dialysis and transplant in Europe. Nephrol Dial Transpl 1991; 6 (1):5-35.
2. Dangri P, Agarwal S, Kaira O P, Rajpal S. Echocardiographic assessment of the left ventricle hypertrophy in patients of chronic renal failure. Indian Journal of Nephrology 2003;13: 92-97.

3. Agarwal S, Dangri P, Kaira O P, Rajpal S. Echocardiographic assessment of cardiac dysfunction in patients of chronic renal failure. JIACM 2003;4(4): 296-303.

4. Shyam C, Sreenivas V. Chronic Kidney Disease: a missing component of integrated control of non-communicable diseases. Correspondence. Indian J Med Res. 2005;122: 451-453.

5. Yashpal, Subramanyam CSV, Gulati VK, Chatterji JC. Pattern of cardiovascular involvement in Chronic Uremia. JAPI 1980; 28:263-267.

6. Parfrey PS, Foley RN, Harnett JD, Kent G M, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in Chronic Uremia. Nephrol Dial Transplant 1996; 11:1277-1285.

7. Amann K, Ritz E. The Heart in Renal failure: Morphological changes of the Myocardium- New Insights. Journal of Clinical and Basic Cardiology 2004; 4(2),109-113.

8. Foley RN, Parfrey PS, Sarnak MJ. Clinical Epidemiology of Cardiovascular Disease in Chronic Renal Disease. American Journal of Kidney Diseases, Nov 1998; 32(5):112-119.

9. Paunovic GJ, Paunovic K et al. Cardiovascular risk factors and Echocardiographic findings in patients on waiting list for cadaveric kidney transplantation. Medicine and Biology 2005; 12(1):28-32.

10. Parfrey PS, Foley RN. The Clinical Epidemiology of Cardiac Disease in Chronic Renal failure. J Am Soc Nephrol 1999, 10:606-1615.

11. Kotchen TA. Hypertensive vascular disease. In: Dennis LK, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL editors. Harrison’s Principles of Internal Medicine. 17th ed. McGraw Hill, New Delhi.2008 :1549-1562.

12. Ruixin Y, Jinzhen W, Shangling P, Weixiong L, Dezhai Y, Yuming C. Sex differences in environmental and genetic factors for hypertension. The American Journal of Medicine 2008; 121(9):811-819.

13. Middleton RJ, Parfrey PS, Foley RN. Left Ventricular Hypertrophy in the Renal patient. J Am Soc Nephro 2001, 12:1079-1084.

14. Tomilina N A, Volgina G V, Bikbov B T, Perepechyonick YuV. Prevelance of the left ventricular hypertrophy and geometric modeling in patients with chronic renal failure.2nd International Congress of Nephrology in Internet.accessed:16/09/2007.

15. Kale S A, Kulkarni N S, Gang S, Ganju A, Shah L, Rajapurkar M M. Left ventricular disorders in patients of end stage renal disease entering hemodialysis programme. Indian Journal of Nephrology 2001; 11:12-16.

16. Datta S, Abharam G, Mathew M. Correlation of Anemia, Secondary Hyperparathyroidism with left ventricular hypertrophy in chronic kidney disease patients. JAPI Sep 2006; 54:699-703.

17. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney International 2002; 61(80):35-38.

18. Bell AC, Adair LS, Popkin BM. Ethnic Differences in the Association between Body Mass Index and hypertension. American Journal of Epidemiology 2002; 155 (4): 346-353

19. Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz DR, Asch SM. Physician barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002, 162:413–20.

20. Roccella EJ, Bowler AE, Ames MV, Horan MJ. Hypertension Knowledge, attitudes, and behavior: 1985 NHIS findings. Public Health Rep. 1986; 101:599–606.